Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination

J. RUSSELL STOTHARD[1]*, MICHELLE C. STANTON[1], AMAYA L. BUSTINDUY[2],
JOSÉ C. SOUSA-FIGUEIREDO[3], GOVERT J. VAN DAM[4], MARTHA BETSON[5],
DAVID WATERHOUSE[1], STEVE WARD[1], FIONA ALLAN[6], AMIR A. HASSAN[7],
MOHAMMAD A. AL-HELAL[8], ZIAD A. MEMISH[8] and DAVID ROLLINSON[6]

[1] *Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK*
[2] *Evelina London Children's Hospital, St Thomas's Hospital, London, UK*
[3] *Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK*
[4] *Leiden Parasitology Diagnostics Group, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands*
[5] *Department of Production and Population Health, Royal Veterinary College, Hatfield, Hertfordshire, UK*
[6] *Parasites and Vectors Division, Life Sciences Department, Natural History Museum, London, UK*
[7] *Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK*
[8] *Ministry of Health, Riyadh, Kingdom of Saudi Arabia*

SUMMARY

Within the World Health Organization 2012–2020 roadmap for control and elimination of schistosomiasis, the scale-up of mass drug administration with praziquantel is set to change the epidemiological landscape across Africa and Arabia. Central in measuring progress is renewed emphasis upon diagnostics which operate at individual, community and environmental levels by assessing reductions in disease, infections and parasite transmission. However, a fundamental tension is revealed between levels for present diagnostic tools, and methods applied in control settings are not necessarily adequate for application in elimination scenarios. Indeed navigating the transition from control to elimination needs careful consideration and planning. In the present context of control, we review current options for diagnosis of schistosomiasis at different levels, highlighting several strengths and weaknesses therein. Future challenges in elimination are raised and we propose that more cost-effective diagnostics and clinical staging algorithms are needed. Using the Kingdom of Saudi Arabia as a contemporary example, embedding new diagnostic methods within the primary care health system is discussed with reference to both urogenital and intestinal schistosomiasis.

Key words: intestinal schistosomiasis, urogenital schistosomiasis, point-of-contact, rapid diagnostic test, morbidity markers, Kingdom of Saudi Arabia.

INTRODUCTION

A century has passed since Robert T. Leiper fully elucidated the lifecycle of the major human schistosomes in Egypt (Leiper, 1915). Recognizing the characteristic egg-spine morphologies of *Schistosoma haematobium* and *Schistosoma mansoni*, he linked these parasites with obligatory freshwater intermediate snail hosts which are today recognized as species within the genera *Bulinus* and *Biomphalaria* (Brown, 1994). By understanding the lifecycle as primarily being played out in freshwater, he pioneered simple control measures, which continue to this day, and avoided infection in man by reducing exposure to schistosome cercariae, the ephemeral larvae shed from aquatic snails which penetrate intact skin (Colley *et al.* 2014).

Since then, the history of schistosomiasis research and control is long and varied (Farley, 1991; Jordan, 2000; Bergquist, 2008). Whilst there have been areas in Africa and the Middle-East where the disease has much receded and even disappeared (Rollinson *et al.* 2013), today the bulk of urogenital and intestinal schistosomiasis is found in rural Africa where it continues to induce ill-health and chronic suffering (WHO, 2013). In many sub-Saharan countries, schistosomiasis either alone or in combination with other neglected tropical diseases (NTDs) can be rife within rural communities that have limited access to safe water, adequate sanitation and hygiene, and have marginalized health care (Colley *et al.* 2014; Pullan *et al.* 2014). In these impoverished settings, the prevalence of HIV may be elevated, yet very little is known of the contributory role of female genital schistosomiasis (Kjetland *et al.* 2014), and the long-term management of these co-infections (Bustinduy *et al.* 2014).

Foundation of schistosomiasis control

Like other NTDs amenable to control by mass drug administration (MDA) with orally administered medications, control of schistosomiasis is firmly

* Corresponding author. Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK. E-mail: jrstoth@liv.ac.uk

based upon increased and regular access to praziquantel (PZQ), often given out in MDA within national control programmes (NCPs) (Fenwick *et al.* 2009; Stothard *et al.* 2013*b*, 2014). The rationale for MDA typically follows a relatively simple treatment algorithm as guided upon parasitological diagnosis of school-aged children (SAC), as outlined in Table 1, and is set within a World Health Organization (WHO) approved strategy of preventive chemotherapy (PC) (WHO, 2006, 2013). However, as not all primary schools are examined, there are often significant gaps in our appreciation of the spatial distribution of disease. Owing to the often complicated geographical distribution and over-dispersion of disease (see below), there may be under- or over-treatment in some areas (Utzinger *et al.* 2009) which has engendered debate (Brooker *et al.* 2009; Standley and Stothard, 2010; Cringoli *et al.* 2013).

In recent years, the mobilization and donation of PZQ has increased considerably (Fenwick *et al.* 2009), fostered by publication of its global need and projection within the WHO 2012–2020 roadmap (WHO, 2013). By outlining the future requirements more clearly, international pledges from major philanthropic agencies and donations from the pharmaceutical sector were formalized. For example, at the London Declaration on NTDs in January 2012, Merck-KGaA announced significant expansion of their annual donation of 20 million PZQ tablets to 250 million by 2016, ring fenced for treatment of SAC alone (Knopp *et al.* 2013*a*; Stothard *et al.* 2013*b*). More recently in Paris during April 2014, further commitment of funds for the control of NTDs by improvement of water and sanitation was made public, hoping to foster intersectoral dialogue for better environmental management of disease.

The WHO roadmap clearly sets out global target numbers for annual treatment with PZQ in SAC and adults. That needed for SAC alone is just under 300 million tablets each year during the 2016–2019 period (WHO, 2013). Reaching these levels can be seen as both scale-up and maintenance phases of PC. From 2019 onwards, the global requirements for PZQ are envisaged to reduce in a scale-down phase. This commensurates with a projected general decline in prevalence of infection, as determined by parasitological methods, and contraction of disease landscape towards more progressively focalized areas and point sources of transmission (Rollinson *et al.* 2013). In these 'hotspots', further reductions in transmission may be more stubborn to achieve, going beyond those which present MDA cycles can provide and requiring additional interventions (WHO, 2013). Somewhat counter-intuitively, perhaps in the drive towards elimination in these settings more aggressive PC strategies may be needed with more frequent MDA cycles.

From control to elimination

Across this changing epidemiological landscape with increased access to MDA, more accurate diagnosis of schistosomiasis will be required given the limitations of parasitological methods which are insensitive (Bergquist *et al.* 2009; Mutapi, 2011; Knopp *et al.* 2013*a*). Some desirable future diagnostic tools and platforms have been identified (Solomon *et al.* 2012; Silva-Moraes *et al.* 2014). Once these new tools are available, they will be judged in terms of their reliability, affordability and scalability and not by supplanting parasitological methods entirely. The latter is important as infection and disease status of individuals and communities will need to be better addressed and sequentially monitored, as reference to parasitological baseline information will still remain for the foreseeable future (Lammie *et al.* 2012; Drain *et al.* 2014). Nonetheless, future monitoring is set to take place over the forthcoming decades and will take advantage of several windows of opportunity within the NCP itself including its scale-up, maintenance and scale-down phases, with the overarching transition from control to elimination (Bergquist *et al.* 2009; Lammie *et al.* 2012; Prichard *et al.* 2012).

Parasitological diagnosis within a community is the underlying mainstay and guide for implementation and evaluation of MDA (Bergquist *et al.* 2009; Cavalcanti *et al.* 2013; Knopp *et al.* 2013*a*); however, there is not one generic diagnostic tool or method entirely ready or equal to achieve all of these tasks (Bergquist *et al.* 2009). To shed light on these aspects, we broadly review current methods used for diagnosis of schistosomiasis at the level of the individual, community and environment, highlighting strengths and weaknesses therein. We then discuss the future challenge managing the transition from control to elimination and use the Kingdom of Saudi Arabia (KSA) as a contemporary regional example (Hotez *et al.* 2012). Here we illustrate that new, cost-effective diagnostics are needed alongside careful consideration and tailoring to embed them within the existing health system thus bridging this transition more securely.

DIAGNOSTICS AT THE INDIVIDUAL LEVEL

In short, there is no fail-safe method for detection of infection or disease in all putative cases; therefore, a combination of methods, sampling and diagnostic acumen is often needed (Utzinger *et al.* 2011; Poole *et al.* 2014). Depending on the presentation and stage of infection, diagnosis of schistosomiasis can be problematic having some unique and specific challenges (Stothard *et al.* 2011). This is broadly due to heterogeneities in exposure through water contact, temporal features within its complex lifecycle and the schistosome's evolved response to mitigate

Table 1. Recommended treatment strategy with PZQ for schistosomiasis (modified from WHO, 2006)

Category	Baseline prevalence among SAC	Action to be taken[a]	
High-risk community	⩾ 50% by parasitological methods[b] (intestinal and urogenital schistosomiasis) or ⩾ 30% by questionnaire for history of haematuria	Treat all SAC (enrolled and not enrolled) once a year	Also treat adults considered to be at risk (from special groups[c] to entire communities living in endemic areas)
Moderate-risk community	⩾ 10% but <50% by parasitological methods (intestinal and urogenital schistosomiasis) or <30% by questionnaire for history of haematuria	Treat all SAC (enrolled and not enrolled) once every 2 years	Also treat adults considered to be at risk (special groups[c] only)
Low-risk community	<10% by parasitological methods (intestinal and urogenital schistosomiasis)	Treat all SAC (enrolled and not enrolled) twice during their primary schooling age (e.g. once on entry and once on exit)	Praziquantel should be available in dispensaries and clinics for treatment of suspected cases

[a] Equivalent to: high-risk community – all SAC and adults require preventive chemotherapy annually; moderate-risk community – 50% of SAC and 20% of adults require preventive chemotherapy annually; low-risk community – 33% of SAC require preventive chemotherapy annually.
[b] For urogenital schistosomiasis, detection of haematuria by chemical reagent strips gives results equivalent to those determined by urine filtration.
[c] Special groups: pregnant and lactating women, groups with occupations involving contact with infected water such as fishermen, farmers, irrigation workers or women in their domestic tasks, to entire communities living in endemic areas.

and avoid the host's immune system (Utzinger *et al*. 2011; Colley *et al*. 2014). Notably, as adult male and female worm pairs remain hidden and inaccessible being tucked away inside the blood vasculature system, they can be rarely quantified directly, but they can be happened upon at autopsy (Jaber and Kirby, 2013) or often accidentally during abdominal surgery (Gulliver *et al*. 2013).

As fecund adult female worms produce numerous eggs each day, diagnosis of infection typically centres upon eggs that are either ejected into the excreta of the human host, in the urine for *S. haematobium* and in stool for *S. mansoni*, or become lodged in host tissues, permitting later biopsy methods such as rectal snips or by cystoscopy (Colley *et al*. 2014). More importantly, trapped eggs release potent antigens that stimulate host immunity, which ultimately concludes in the formulation of granulomata, and other chronic inflammatory responses, to 'wall off' damage. It is the accumulation of such granulomata and fibrotic sequelae which gives rise to the primary mischief of chronic schistosomiasis, manifesting as bowel, hepatosplenic and urogenital tract disease (Colley *et al*. 2014). Less usual disease presentations are known, e.g. sequelae in the cerebrum and spine (Carod Artal, 2012).

It is this subtle distinction between the numbers of eggs released *vs* those that remain trapped that causes confusion over the importance between active egg-laying infections *vs* chronic disease. The correlate between number of eggs observed in excreta and level of overt pathology accumulated through time is not straightforward. To bring some epidemiological consensus, WHO guidelines classify the severity of

infection by enumeration of shed eggs per gram (EPG) of stool, by Kato-Katz examination, as light (<100 EPG), moderate (>100–399 EPG) and heavy (⩾ 400 EPG) or eggs per 10 mL of urine by filtration, as light (<50 eggs) or heavy (⩾ 50 eggs) (WHO, 2006). Upon classification of the present intensity of infection, some prediction of the future occurrence of overt disease is possible. However, this relationship is imprecise and the clinical significance of even light egg intensity infections is being upwardly revised (Colley *et al*. 2014). Moreover, in high transmission environments it has been shown that preschool-aged children (PSAC) have overt morbidity yet 'light' egg-patent infection (Poole *et al*. 2014). Thus the detrimental effects of infection at such an early age are underestimated and it is important to note that the treatment needs of these infected PSAC with PZQ do not feature within the WHO 2012–2020 projection (Stothard *et al*. 2013*a*).

Any single measure of the intensity of egg-patent infection in stool or urine is an imprecise measure as it is a snap shot in time and does not estimate the duration of infection, which may be of several years and therefore poorly correlates with the cumulative total of trapped eggs. The significance of the distinction between active and chronic schistosomiasis may become blurred, especially in previously treated individuals, as does the disease status of an individual who has been 'cured' after treatment with PZQ which is measured by cessation of egg excretion (Stothard *et al*. 2013*b*, 2014). In the context of control, it is this latter point that has important implications in the choice of diagnostics, for at the individual level those who are treatment-naïve or

have had repeated treatment cycles of PZQ may have entirely different dynamics of egg excretion, confounding the application of diagnostic tools (Stothard *et al.* 2011; Stete *et al.* 2012). By way of example, in a UK travel clinic setting re-infection can be safely ruled out while in the endemic setting resolution between incomplete cure and rapid re-infection is not always possible (Meltzer and Schwartz, 2013).

Available diagnostic methods and proxy markers of morbidity

Whilst there are advanced methods in diagnostic imagery, i.e. magnetic resonance imagery and poly-merase chain reaction (PCR) assays for detection of *Schistosoma* from extracted DNA from stool, urine or vaginal lavage, these do not feature within routine repertoire of NCPs (Webster *et al.* 2009; Kjetland *et al.* 2012; Kato-Hayashi *et al.* 2013; Lodh *et al.* 2013, 2014; Vinkeles-Melchers *et al.* 2014). Figure 1 lists and outlines the strengths and weaknesses of commonly used diagnostic tools and methods which are either commercially available or in widespread use within NCPs. To compare the performance of each method in control or elimination settings, each technique is graded in simple terms of '–' (not applicable), '+' (applicable), '++' (desirable) and '+++' (optimal), at either baseline surveys, during PZQ efficacy investigations or in subsequent follow-ups likely as repeated in consecutive cross-sectional or longitudinal surveys.

Using blood and sera

Whilst eosinophilia is widely used in the UK and elsewhere as generic tests for helminthiasis (Logan *et al.* 2013; Paugam *et al.* 2013), schistosomiasis can be diagnosed on the basis of serology from clotted finger-prick blood by either immunological detection of circulating antigens, i.e. circulating cathodic antigen (CCA) and circulating anodic antigen (CAA) which are important not to be confused as they have distinct structural and diagnostic charac-teristics although both are released from the worms themselves, or upon detection of host antibodies to schistosome egg antigens (SEA) mainly by immu-noglobulin G (Stothard *et al.* 2009*c*, 2011). It is also possible to detect antibodies to adult worm or cercarial antigens but these assays are not yet in routine use and typical of antibody-based methods, these cannot differentiate between active and past infection (Coulibaly *et al.* 2013; Dawson *et al.* 2013). The relative merits of serological detection, which are very sensitive, have been discussed elsewhere but an immediate drawback of these methods is that they do not discriminate between the different forms of intestinal or urogenital schistosomiasis, and are

unable to identify mixed infections of both schisto-some species.

In terms of commercial production, there is a robust SEA-enzyme linked immunosorbent assay (ELISA) kit retailed by SCIMEDX (New Jersey, USA) which is applicable in field-based laboratories, having a raw per-test cost of US$1·5 not including the price of a lancet, centrifugation equipment or staff processing time. Although ELISA assays for CCA and CAA exist, these are restricted to specialist laboratories that typically use in-house reagents. A point-of-contact (POC) lateral flow test is being developed for detection of CAA in sera and urine with funding support from the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) at the University of Georgia, USA.

The advantage of direct detection of CAA/CCA is that these antigens are released in the vomitus of extant worms and provide a useful proxy marker of adult worm burden or as a pharmacodynamic marker of worm death following treatment with PZQ. By contrast, no such relationship exists with antibody titres to SEA which remain positive long after treatment, being therefore unable to differentiate between active and past infections. Nevertheless, antibody methods have significant appeal in moni-toring the rate of sero-conversion of naïve groups when elimination criteria are being developed. Anaemia is associated with schistosomiasis, as caused by a variety of mechanisms (Friedman *et al.* 2005), and a significant correlation between increasing infection intensities and decreasing haemoglobin levels exists (Rollinson *et al.* 2005; Koukounari *et al.* 2006; Fenwick *et al.* 2009; Green *et al.* 2011). The POC technologies to measure finger-prick haemoglobin levels in remote and resource poor settings is well developed, portable and robust with Hemocue photometers (Hemocue Ltd; Ängelholm, Sweden) and can be amalgamated into general disease surveillance alongside schistoso-miasis.

Using the stool

The detection of schistosome eggs in stool is often seen as the 'gold' standard and WHO treatment guidelines are developed upon the prevalence of egg-patent infections of *S. mansoni*, as determined upon examination of a single Kato-Katz thick smear by light microscopy. It is well known that a single Kato-Katz thick smear is insensitive but can be bolstered by repeated examination(s) of consecutive stool samples. In this operational setting, significant doubling or tripling of costs by increased sampling effort often goes beyond available resources and logistics of the survey team. In addition, in some cultural settings, in particular in Arabia, the pro-vision of stool is problematic as being considered

Fig. 1. Schematic depicting the present diagnostic tools for schistosomiasis that are either commercially available or in widespread use within NCPs, e.g. during baseline surveys, drug efficacy investigations and cross-sectional or longitudinal follow-ups. No mentioned diagnostics can infer precisely the adult worm burden or level of overt disease so a rating system of '–' (not applicable), '?' (questionable), '+' (applicable), '++' (desirable) and '+++' (optimal) is used. At the individual level, the distinction between traveller or endemic and adult or child should be made as this might frame the timing of last exposure. In so doing this highlights the possibility of hyper-infection where juvenile and adult worms co-circulate or are sufficiently mature to have commenced egg production. The background history of treatment with PZQ is also important and might confound diagnostic methods such as serology. [Notes: (A) serology is the 'gold' standard for first diagnosis, especially in the UK when travellers have returned home by 3-month post-exposure; (B) urine sampling is the most convenient but analysis of semen and vaginal lavage is important; (C) several different reagent strips exist and useful for detection of infection and disease, e.g. albuminuria and creatinine.]

an unclean activity. Greater sensitivity can be accomplished with faecal concentration techniques using formol-ether (i.e. Ritchie technique) but this is more cumbersome and equipment needy than Kato-Katz (WHO, 2006). As mentioned previously, whilst the detection of eggs in stool can be considered definitive, the absence of eggs does not necessarily infer an absence of extant worms or chronic disease, thus better direct markers of morbidity are needed. This is especially true when considering the detection and grading of genital schistosomiasis in women and men (Kjetland *et al.* 2012).

Recent proxy markers of morbidity that are commercially available include the use of rapid diagnostic tests (RDTs) for faecal occult blood (FOB) (Betson *et al.* 2010, 2012; Bustinduy *et al.* 2013*b*). These may either take the form of immuno-chromatographic dipsticks or specialist reagent strips which have been shown to have strong associations with egg-patent infections of *S. mansoni*. With the development of RDTs that measure faecal calprotectin, preliminary application of these tests has shown strong associations with intestinal schistosomiasis, as might be expected because when eggs perforate the bowel they initiate both a release of blood and localized inflammation (Bustinduy *et al.* 2013*b*). As FOB and calprotectin tests were developed for applications outside the use in detection of intestinal schistosomiasis (i.e. screening for colorectal cancer and inflammatory bowel disease syndrome), their market and commercial availability is likely set to be sustained over the next decade. Each test presently retails at US$0·5 and US$12·5 per test, respectively.

Whilst it is outside the remit of the present paper to discuss more broadly the sustainability of diagnostic tests (see Webster *et al.* 2009), it is worthy to note that without outside subsidy or philanthropic support the current diagnostic market for schistosomiasis in sub-Saharan Africa is likely not self-sustaining. Nonetheless, a first step towards encouragement of this market was taken in August 2013 when the Task Force for Global Health coordinated an inception meeting that developed key target product profiles for a variety of future diagnostic needs. It remains to be seen how the commercial

diagnostic sector will respond or how the diagnostic market will expand.

Using the urine

The cardinal sign of urogenital schistosomiasis is frank blood in urine, being recognized in areas of endemic haematuria as being directly attributable to *S. haematobium* infection (Jordan, 2000). Using this feature, red-urine questionnaire methods have been used and incorporated into WHO treatment guidelines, e.g. when prevalence of recalled red-urine in SAC exceeds 30% the immediate area is considered high risk (WHO, 2006). Whilst the performance of the red-urine questionnaire has been debated (Stothard *et al.* 2002*a*), for not all SAC accurately recognize their urine colour, it remains to be ascertained how the questionnaire fares when used in areas that have had prior MDA (Stothard *et al.* 2002*a*,*b*).

The operational 'gold' standard is syringe filtration of 10 mL of fresh urine collected between 10 am and 2 pm with filtrates viewed under the light microscope and enumeration of eggs. Recognized as being simple and cheap urine filtration became favoured over other methods, such as centrifugation, for being more pragmatic for school-based surveys where on-site electricity was not available. Like faecal examination, urine filtration may be conducted on samples on consecutive days but the gains in diagnostic sensitivity are not as dramatic as those in Kato-Katz (Stete *et al.* 2012).

In resource-poor settings, reagent strips that detect microhaematuria have advantages over urine filtration and have been endorsed by WHO as providing broadly equivalent results and have been subjected to a recent systematic review. As there is a variety of reagent strip manufacturers (King and Bertsch, 2013), it is known that the quality of product can vary, but foremost in reliability and use has been Hemastix® (Siemens Healthcare Diagnostics Products Ltd; Llanberis, UK). Each reagent strip is typically US$0·25 and the diagnostic performance of these strips as shown in a recent meta-analysis to be very favourable (King and Bertsch, 2013), in a long-standing control programme (French *et al.* 2007; Stothard *et al.* 2009*a*; Knopp *et al.* 2013*b*) on Zanzibar, Tanzania and in cross-sectional surveys in South Sudan (Robinson *et al.* 2009).

In line with other reagent strips that detect additional urological parameters, e.g. urine-albumin or urine-to-creatinine ratio, these have also been proven useful to detect infection and be useful as a proxy marker of urinary tract disease (Sousa-Figueiredo *et al.* 2009; Stothard *et al.* 2009*b*). With advances in portable machine readers, e.g. CLINITEK Status® (Siemens Healthcare Diagnostics Products Ltd; Llanberis, UK), possibilities now exist for automation of reading strips. Noteworthy is another commercially available urine-albumin assay (Hemocue Ltd; Ängelholm, Sweden), which has proven particularly useful in morbidity surveys in SAC (Rollinson *et al.* 2005) and PSAC (Poole *et al.* 2014).

As circulating *Schistosoma* antigens are excreted in the host urine, the development of urine-based lateral flow immuno-chromatographic dipsticks was proven possible and first developed into commercial production by EVL, the Netherlands in 2002 as the 1-step CCA assay (Stothard, 2009). After initial evaluations in the field (Stothard *et al.* 2006) and change of manufacturer to Rapid Medical Diagnostics (Cape Town, South Africa), the urine-CCA dipstick underwent a comprehensive trial for the detection of intestinal schistosomiasis in SAC. Retailing at slightly less than US$1·75 per dipstick the test has significant advantages over Kato-Katz examinations and has been informally documented by WHO in mapping the distribution of intestinal schistosomiasis in SAC (Standley *et al.* 2009). The urine-CCA dipstick has also been used widely in monitoring intestinal schistosomiasis in PSAC and appears to be useful as an indicator of the efficacy of PZQ (Colley *et al.* 2013). Its performance for detection of urogenital schistosomiasis is much poorer and may be confounded by cryptic co-infections with *S. mansoni*. With funding from SCORE a urine-CAA dipstick is being developed with much better diagnostic performance for both types of schistosomiasis (van Dam *et al.* 2013).

Additional markers of morbidity

The detrimental impact of schistosomiasis goes beyond that of direct markers of morbidity and can cause general effects on disability, growth, multi-organ damage and fitness (Balen *et al.* 2006; Colley *et al.* 2014). In a similar manner to Fig. 1, a summary list is compiled in Fig. 2 and attempts to compare their usefulness at baseline surveys and subsequent follow-ups. The use of portable ultrasonography is perhaps the best method to visualize morbidity directly (Strahan *et al.* 2013). The success of some methods in terms of monitoring is dependent upon the length of time between follow-ups (Utzinger *et al.* 2011). For example, qualitative and quantitative changes in responses to quality-of-life questionnaires (Terer *et al.* 2013; Won *et al.* 2014) and clinical palpation studies likely have a slower temporal dynamic to fitness tests (Bustinduy *et al.* 2011, 2013*a*; Gurarie *et al.* 2011). Although useful in quantification of general morbidity during control phases of NCPs, it remains to be seen how these measures of disease, or associated ill-health, will be used as NCPs move towards elimination settings when active egg-patent infections are proven absent (Utzinger *et al.* 2009, 2011).

Fig. 2. Schematic depicting the additional diagnostic tools for detection of morbidity associated with schistosomiasis. In this instance, it is relatively unimportant to know the egg excretion or adult worm burdens of the child, since morbidity measures are directly observed and not inferred, but the setting in which they are used is context-specific. A rating system of '+' (applicable), '++' (desirable) and '+++' (optimal) is therefore used in comparison to baseline and follow-up, and judged here annually, i.e. short-term changes, but the intervening period could potentially range across months, years or decades.

Measuring performance of PZQ

Despite being widely used, the background information on pharmacokinetics and pharmacodynamics of PZQ is surprisingly meagre (Colley *et al.* 2014; Olliaro *et al.* 2014). The drug is licensed for administration at 2 dosages: 40 or 60 mg kg^{-1}, in SAC and adults but when used for treatment of PSAC is in an off-label setting (Garba *et al.* 2013; Stothard *et al.* 2013*a*). It is outside the scope of the present review to assess the pharmacokinetics of PZQ, but consideration of pharmacodynamics is needed given the overlap with diagnostic tests.

Along with any MDA there are always concerns of the emergence of drug resistance and WHO have issued new informal guidelines on conducting initial drug efficacy checks. These centre upon definitions of parasitological cure and egg reduction rates (Montresor, 2011) which are also addressed by Levecke *et al.* (2014) and the duration between treatment and follow-up (typically 21–28 days to circumvent the confusion over maturing schistosomes which are drug insensitive) (Scherrer *et al.* 2009; Stete *et al.* 2012; Garba *et al.* 2013; Tchueme-Tchuente *et al.* 2013; Webster *et al.* 2013). Similarly, with the human immunodeficiency virus (HIV) epidemic in sub-Saharan Africa still expanding and with it the expansion of access to antiretroviral drug schemes, the performance of PZQ against this background of HIV-infected individuals needs some consideration (Bustinduy *et al.* 2014).

It is known that in high transmission areas parasitological cure when PZQ is administered at 40 mg kg^{-1} can be low (50–75%) which suggests that the killing effect of PZQ is sub-optimal (Stothard *et al.* 2013*b*) as has been seen in PSAC (Sousa-Figueiredo *et al.* 2012). There is, however, the added confounding effect that worms may cease production of eggs while temporarily stunned by PZQ and then later recover fecundity to again shed eggs (Tchueme-Tchuente *et al.* 2013). A major diagnostic challenge remains to develop a diagnostic test that can explicitly measure worm death, and for better convenience within a shorter period than the present 21–28 days (Scherrer *et al.* 2009; Utzinger *et al.* 2009).

Of the tests presently under development it might appear that the POC-CAA test for sera and/or urine could be appropriate. Without such a sensitive test, future monitoring and evaluation of the performance of PZQ in areas characterized by 'light' egg-patent infections will become ever more demanding as several hundreds of children will need to be screened to find sufficient numbers of those with egg counts that can be measured reliably. A forthcoming situation somewhat analogous to the present difficulties in assessing the exact curative performance of PZQ in travellers who have sero-converted yet egg-patent infections in their excreta could not be proven (Logan *et al.* 2013).

DIAGNOSTICS AT THE COMMUNITY LEVEL

As outlined in Table 1, parasitological diagnosis of infections within SAC serves as a convenient anchor point to decide where local MDA is needed. In the context of control, not all primary schools are surveyed, for to do so would consume both time and financial resources typically outside that available

Fig. 3. Examples of the disease landscape in control and elimination settings taken from contemporary data. The panel in green depicts the distribution of 200 schools as recently surveyed in Namibia (left) when 60 children per school were examined by CCA-urine dipsticks and reagent strips for microhaematuria. Prevalence of general schistosomiasis by school is then ranked in ascending order in the associated bar chart below (dotted line – mean prevalence (7·9%) of infection across schools, where the disease is present; dashed line – mean prevalence (6·5%) of infection across all 200 schools; blue line – a descriptive trend line; median prevalence (3·3%)). In elimination settings, the distribution of schools with raised prevalence likely tracks those before with higher prevalence and now may require more aggressive MDA. While many schools (and those that remain to be sampled) likely trend towards absence of infection as inferred with CCA-urine dipsticks and reagent strips, these levels likely under-estimate the true prevalence of infection, especially if a more sensitive diagnostic and larger sample size of examined children was used (dotted line – mean prevalence (6·3%) of infection across schools where the disease is present; dashed line – mean prevalence (2·1%) of infection across all 200 schools; blue line – a descriptive trend line; median prevalence (0·0%)).

within the NCP. Thus the delivery of MDA is a working compromise between areas *thought* to be at or are *proven* to be at-risk. The scenario can be illustrated in Fig. 3 which depicts information taken from a real landscape as recently mapped in Namibia where 200 primary schools have been visited and 60 children within each school examined using a combination of urine-CCA dipsticks and Hemastix®.

Typical of schistosomiasis is the often complex distribution of high, medium and low prevalence schools (Utzinger *et al.* 2009). In this instance, only schools that have been surveyed have been depicted, and there remain a further 600 schools not surveyed. Nonetheless when the sampled schools are assigned to the lowest administrative unit, and mean prevalence is calculated, typically across 20 schools, this

gives a fair reflection of the local endemicity of schistosomiasis which is used to set the MDA cycle. In this example, the mean prevalence across all sampled schools is less than 10%; however, there is a great amount of variability in school-level estimated prevalence such that in several schools, prevalence exceeds 50%. Across these 200 schools, there are 18 schools that have prevalence of >10%. A corollary of this is that of the 400 schools which remain to be sampled, assuming a similar ratio of 0·09%, some 36 schools would be expected to have a prevalence of 10% or greater. Without conducting further on the ground surveillance their precise geographical locations will be unknown. With subsequent rounds of MDA the general prevalence of infection across all schools treated will decline and the pattern of

Fig. 4. (A) Idealized surface plot to depict how the number of diagnostic tests used increases as the prevalence by school declines. Within high-to-moderate prevalence schools less diagnostic tests are needed to guide local MDA; however, when prevalence declines towards low levels and becomes a fraction of 1%, the use of individual diagnostic tests will increase by 1–2 orders of magnitude at each evaluation. (B) Across this hypothetical surface that transitions from control to elimination interventions, there will be a tipping point when the costs for diagnostics outweigh that of MDA treatment(s). If more than 1 diagnostic tool or strategy is used concurrently then the 'tipping' point will be dynamic and context specific to the epidemiological landscape of either intestinal or urogenital schistosomiasis. At one end of this spectrum, with present diagnostic tools and methods, it will be much more expensive to prove the absence of infection rather than undertake unneeded MDA(s).

infected schools will change, contingent upon local transmission factors, e.g. water contact, compatible snail distributions, etc. Even with advanced geospatial models, it is not yet possible to predict how prevalence within each sampled schools will trend (Brooker *et al*. 2009; Stothard, 2009). Whilst the total number of sampled schools with prevalence >10% is reduced, the spatial distribution will not be explicit until all non-sampled schools are surveyed.

The implications of this are 2-fold. First, to revise subsequent MDA schedules a resurvey of the same schools is needed (likely with the same diagnostic as not to incur diagnostic bias) unless there is a switch to a more sensitive diagnostic, as used in low transmission areas (Cavalcanti *et al*. 2013). In so doing the prevalence ascertained with the new diagnostic will likely inflate that measured previously, potentially confusing MDA treatment regimes until these are defined with the new diagnostic. Second, as the prevalence of disease declines by school, the current sampling frame of 60 children per school will likely be insufficient to identify subsequent declines in prevalence by ±2% with statistical significance. Therefore when prevalence is pushed to near unity or lower, sample sizes within each school will inflate and nearly all the children will be testing negative (Knopp *et al*. 2013*a*). There is, of course, the possibility to reduce the number of tests used by grouping, or pooling, specimens but the theory and practicalities of this are only starting to be developed (Mitchell and Pagano, 2012; Prichard *et al*. 2012;

Cringoli *et al*. 2013). Moreover, surveillance in the non-sampled schools will be needed and increase the sample frame of school sampling at each time point. Using large numbers of diagnostic tests as applied within all schools has a somewhat perverse cost-effectiveness scenario, in that it may be more costly to prove the disease absent rather than continue with MDA when the disease is much diminished or was actually not there.

Are diagnostics cost-effective in elimination scenarios?

To shed light on this unusual implication, Fig. 4 attempts to frame the argument. To determine the prevalence of infection to a reasonable level of precision and identify whether it is high risk, a small sample size of 15 children is sufficient if following a lot quality assurance sample frame (LQAS) (Brooker *et al*. 2005, 2009) thus only 10s of tests are typically used to identify high and medium prevalence schools (Olives *et al*. 2012). When the prevalence of disease is lower, then local sample size increases to cater for the statistical precision necessary to differentiate minor changes in prevalence, e.g. ±2%. As one attempts to prove the infection prevalence is a fraction of 1% then sample sizes will continue to inflate, ultimately using 100s or possibly 1000s of tests, which nearly all will be negative.

Thus if the average raw cost of a diagnostic is US\$1·0 then up to several hundred dollars per school or location will be needed to prove that the disease

is not there. By contrast, the price of delivery of treatment to the same location is a fraction of this cost. Implicitly, there will be a tipping point in costs when more money will be spent on diagnostics than that spent on treatments (Fig. 4B). Presently, this tipping point is not known and should be more explicitly defined or else the economics of elimination will make very little financial sense, unless international agencies are reconciled to short-term ($\leqslant 10$ years) and long-term (>10 years) projections. The same logical arguments have been used before to justify the use of RDTs in initial mapping (Stothard, 2009) and will also remain true when schistosomes are to be screened in the environment for their absence.

DIAGNOSTICS FOR SCHISTOSOMES IN THE ENVIRONMENT

As the schistosome spends a considerable proportion of its time in aquatic environments, chiefly developing within compatible populations of *Bulinus* or *Biomphalaria* snails, some consideration in the use of diagnostics in snail intermediate hosts is needed (Rollinson *et al.* 2001, 2013), especially in elimination stages when transmission foci are to be progressively targeted (Rollinson *et al.* 2009). Although it is relatively simple to collect freshwater snails and inspect them for evidence of infection by natural shedding of schistosome cercariae or by crushing them to search for sporocyst, it is generally accepted that these measures are insensitive, for only a small proportion of snails ($<5\%$) harbour patent infection (Rollinson *et al.* 2001, 2009). There have been attempts to detect cercariae directly in freshwater bodies but the technology to do so needs improvement as often large volumes of water need to be filtered (Mull *et al.* 2010; Rollinson *et al.* 2013).

The development of molecular tests to detect schistosomes in snails first utilized antibody methods to *Schistosoma* proteins (Hamburger *et al.* 1989), but this technology has been supplanted by PCR and latterly with experimental loop-mediated isothermal amplification (LAMP) assays (Hamburger *et al.* 2004, 2013; Abbasi *et al.* 2010). Using real-time or traditional PCR approaches it is possible to screen field-caught *Bulinus* and *Biomphalaria*, as well as non-target molluscs, for evidence of schistosome infection (Akinwale *et al.* 2011; Kane *et al.* 2013; Standley *et al.* 2013). As an alternative, it is possible to deploy laboratory-bred snails in cages within putative transmission foci for a short 2- to 3-day period then to be later screened by PCR to assess whether any miracidia were present (Allan *et al.* 2013). This has been undertaken recently on Unguja, Zanzibar (Fig. 5), as part of ongoing attempts to eliminate urogenital schistosomiasis from the islands. Using such approaches at water contact sites around Chaani school, the detection of snails positive for

PCR is good indication of active contamination of the water habitats by infected children with *S. haematobium*.

Expanding upon this sampling strategy, it is possible to scale-up the deployment of caged snails to verify *ad hoc* an absence of transmission; however, experiments such as this need to be repeated at several time points throughout the year to ensure there is no seasonality of transmission (Allan *et al.* 2013; Rollinson *et al.* 2013). This increased sampling, in turn, inflates budgets and resources needed for such detailed monitoring (Knopp *et al.* 2013*b*, *c*; Rollinson *et al.* 2013). An additional complicating factor is that some of the DNA probes cross-react with non-human schistosomes and therefore assays can be confounded by the presence of veterinary schistosomes such as *Schistosoma bovis* (Rollinson *et al.* 2001, 2009). As there are presently no specific WHO guidelines to frame these activities even in generic terms, the requirements necessary for certification of elimination of transmission in the environmental will remain ambiguous (Rollinson *et al.* 2013).

SCHISTSOSOMIASIS IN THE KSA

In the WHO 2012–2020 roadmap, countries have been assigned into 1 of 3 categories and for the WHO-Eastern Mediterranean Region Office (EMRO) these are: (1) countries requiring PC (Egypt, Somalia, South Sudan, Sudan, Yemen), (2) countries requiring updating for planning and implementation purposes (Iraq, Libya, Oman, KSA, Syrian Arab Republic); and (3) countries requiring evaluation in order to verify if interruption of transmission has been achieved (Djibouti, Iran, Jordan, Lebanon, Morocco and Tunisia). The situation of schistosomiasis in KSA serves as a useful example of a country in transition from control to elimination as shown in the schematic map of Fig. 6 which outlines the areas of KSA where both intestinal and urogenital schistosomiasis are now found, albeit at egg-patent prevalence of <1%.

Beginning in 1974, KSA has sustained and adapted its NCP against schistosomiasis through a combination of treatment, health education and snail control with both chemical and environmental methods (Warrell, 1993; Hotez *et al.* 2012). Originally implemented as a vertical programme, major declines from 11 to 1·9%, in general prevalence of infection, were achieved in the 1980s through the combined use of PZQ and chemical mollusciciding with Bayluscide®, and today KSA remains the largest purchaser of this product.

At the end of the 1980s with further effort still needed, the NCP was embedded into the primary health care (PHC) system in order to increase to at least 80% of the target population coverage, which then provided a more stable infrastructure to offer routine parasitological diagnostics (examination of

Fig. 5. Monitoring schistosomes in the environment using caged snails as sentinel miracidial traps. (A) Labelling laboratory bred *Bulinus* with enamel paint. (B) Plastic cage used to contain snails when deployed in freshwater habitat. (C) Submerged cage within Chaani stream tethered by string to an over-hanging branch. (D) Map of Unguja (inset) depicting Chaani school (cross) with an associated sketch map of the stream passing through Chaani. Along the stream snail cages were deployed at 7 monitoring stations for 2 days. Snails were then examined by PCR for evidence of schistosome DNA. Pie charts denote the prevalence of infection/exposure associated with each cage evidencing the presence of miracidia at 5 sites.

stool by glycerol sedimentation for *S. mansoni* eggs and centrifugation of urine for *S. haematobium* eggs) with better opportunities to administer chemotherapy to infected cases (Ageel and Amin, 1997; Al Morad and Khan, 2001; Ghahtani and Amin, 2005). Combined with general socio-economic improvement, continued use of molluscicides and active parasitological surveillance, schistosomiasis is now at very low levels of prevalence in certain areas of KSA. Indeed regions of KSA can be classified in 3 categories: (a) disease free, (b) transmission interrupted; and (c) low transmission (general prevalence <1%), see Fig. 6.

An interesting feature of pushing schistosomiasis to these very low levels raises the importance of containment of imported infections and a maintenance phase in use of molluscicides to prevent any reactivation of any previous transmission foci. From 2010 onwards, imported infections progressively outnumbered those that were considered autochthonous, i.e. locally acquired, and it is a challenge to the health surveillance system to maintain a test-and-treat strategy when illegal immigrants enter into the country, especially those from Yemen where urogenital and intestinal schistosomiasis is endemic

(Oshish *et al*. 2011; Sady *et al*. 2013). Similarly many of the wadi and river systems in Jazan originate within the Yemen and there remains the constant threat of populations of *Bulinus* and *Biomphalaria* being washed-in during times of flooding. Indeed, such an occurrence has recently taken place in March 2014 and is being investigated with targeted epidemiological surveys.

Thus moving forward from control to elimination of schistosomiasis in KSA and elsewhere in Arabia and Africa, 2 major challenges need to be addressed (Cavalcanti *et al*. 2013; Knopp *et al*. 2013*a*). First when and how can the switch over from parasitological methods to serological- and antigen-detection screening occur and be best harmonized within the PHC? Second, with newly adopted tools and sampling strategies how can imported infections be best contained to ensure there is no recrudescence of older foci following from reintroduction of schistosomes (Prichard *et al*. 2012). Before one diagnostic technology supplants another, cost-effectiveness calculations and health system simulations should be conducted to avoid unnecessary duplications or parallelisms, and by phasing-in quality assured tools and protocols it will not over-burden

Fig. 6. Outline map of the KSA with capital Riyadh depicted. Major administrative boundaries are shown
and associated status of schistosomiasis therein is indicated by shaded circles. (A) Al-Jouf; (B) Tabuk; (C) Hail;
(D) Al-Madena and Al Monawarah; (E) Al Qasim; (F) Riyadh; (G) Najran; (H) Taif, Makkah, Jeddah, Al Qunfudhah
and Alith; (I) Al-Baha; (J) Bishah and Assir; (K) Jazan.

the PHC and achieve enhanced control. Of the two
tests which could be most easily applied above
parasitological methods, first, scaled-up screening
of urine with CCA-tests would increase frontline
surveillance for intestinal schistosomiasis and could
mesh well with existing filtration methods for
detection of eggs of *S. haematobium*, being used
both in immigrants and in communities around
putative transmission foci; second, serological analy-
sis for host antibodies to SEA could be provided as a
passive surveillance in the PHC centres to augment
active case finding near or around putative trans-
mission foci. Whilst the use of PCR in screening
snails would help identify more precisely sites
contamination of either *S. mansoni* or *S. haema-
tobium*, this activity would be best performed outside
the primary health care unit and within specialist
molecular diagnostic laboratories at the district level
but coordinated within the Ministry of Health at the
central level.

OUTLOOK

In the drive for scale-up of MDA with PZQ,
appropriate diagnostics still plays a central role in
guiding and assessing the impact of PC. It is clear that
in control settings the number of diagnostic tests used

to define whether or not MDA is needed is much less
than that needed in elimination settings. In this
scenario, to prove that the disease is significantly less
than 1%, 100s or possibly 1000s of tests are needed.
Conventional parasitological sampling will likely
continue to play an important future role, which
may hamper the introduction of novel more sensitive
diagnostics, until a financial tipping point is reached.
Upon reaching this point, it should have been shown
previously that there is a clear cost-effective benefit
in better diagnostics offset against MDA costs.
Monitoring the performance of PZQ with pharma-
codynamic markers other than egg excretion, such as
measuring levels of circulating schistosome antigens,
should be encouraged.

REFERENCES

Abbasi, I., King, C. H., Muchiri, E. M. and Hamburger, J. (2010). Detection of *Schistosoma mansoni* and *Schistosoma haematobium* DNA by loop-mediated isothermal amplification: identification of infected snails from early prepatency. *American Journal of Tropical Medicine and Hygiene* **83**, 427–432.

Ageel, A. R. M. and Amin, M. A. (1997). Integration of schistosomiasis-control activities into the primary-health-care system in the Gizan region, Saudi Arabia. *Annals of Tropical Medicine and Parasitology* **91**, 907–915.

Akinwale, O. P., Kane, R. A., Rollinson, D., Stothard, J. R., Ajayi, M. B., Akande, D. O., Ogungbemi, M. O., Duker, C., Gyang, P. V. and Adeleke, M. A. (2011). Molecular approaches to the identification of *Bulinus* species in south-west Nigeria and observations on natural snail infections with schistosomes. *Journal of Helminthology* **85**, 283–293.

Al Ghahtani, A. G. and Amin, M. A. (2005). Progress achieved in the elimination of schistosomiasis from the Jazan region of Saudi Arabia. *Annals of Tropical Medicine and Parasitology* **99**, 483–490.

Allan, F., Dunn, A. M., Emery, A. M., Stothard, J. R., Johnston, D. A., Kane, R. A., Khamis, A. N., Mohammed, K. A. and Rollinson, D. (2013). Use of sentinel snails for the detection of *Schistosoma haematobium* transmission on Zanzibar and observations on transmission patterns. *Acta Tropica* **128**, 234–240.

Balen, J., Stothard, J. R., Kabatereine, N. B., Tukahebwa, E. M., Kazibwe, F., Whawell, S., Webster, J. P., Utzinger, J. and Fenwick, A. (2006). Morbidity due to *Schistosoma mansoni*: an epidemiological assessment of distended abdomen syndrome in Ugandan school children with observations before and 1-year after anthelminthic chemotherapy. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **100**, 1039–1048.

Bergquist, R. (2008). A century of schistosomiasis research. *Acta Tropica* **108**, 65–68.

Bergquist, R., Johansen, M. V. and Utzinger, J. (2009). Diagnostic dilemmas in helminthology: what tools to use and when? *Trends in Parasitology* **25**, 151–156.

Betson, M., Figueiredo, J. C. S., Rowell, C., Kabatereine, N. B. and Stothard, J. R. (2010). Intestinal schistosomiasis in mothers and young children in Uganda: investigation of field-applicable markers of bowel morbidity. *American Journal of Tropical Medicine and Hygiene* **83**, 1048–1055.

Betson, M., Sousa-Figueiredo, J. C., Kabatereine, N. B. and Stothard, J. R. (2012). Use of fecal occult blood tests as epidemiologic indicators of morbidity associated with intestinal schistosomiasis during preventive chemotherapy in young children. *American Journal of Tropical Medicine and Hygiene* **87**, 694–700.

Brooker, S., Kabatereine, N. B., Myatt, M., Stothard, J. R. and Fenwick, A. (2005). Rapid assessment of *Schistosoma mansoni*: the validity, applicability and cost-effectiveness of the lot quality assurance sampling method in Uganda. *Tropical Medicine and International Health* **10**, 647–658.

Brooker, S., Kabatereine, N. B., Gyapong, J. O., Stothard, J. R. and Utzinger, J. (2009). Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in Africa. *Parasitology* **136**, 1707–1718.

Brown, D. S. (1994). *Freshwater Snails of Africa and their Medical Importance.* Taylor & Francis Ltd., London.

Bustinduy, A., King, C., Scott, J., Appleton, S., Sousa-Figueiredo, J. C., Betson, M. and Stothard, J. R. (2014). HIV and schistosomiasis co-infection in African children. *Lancet Infectious Disease* **14**, 640–649.

Bustinduy, A. L., Thomas, C. L., Fiutem, J. J., Parraga, I. M., Mungai, P. L., Muchiri, E. M., Mutuku, F., Kitron, U. and King, C. H. (2011). Measuring fitness of Kenyan children with polyparasitic infections using the 20-meter shuttle run test as a morbidity metric. *PLoS Neglected Tropical Diseases* **5**, e1213.

Bustinduy, A. L., Parraga, I. M., Thomas, C. L., Mungai, P. L., Mutuku, F., Muchiri, E. M., Kitron, U. and King, C. H. (2013a). Impact of polyparasitic infections on anemia and undernutrition among Kenyan children living in a *Schistosoma haematobium* – endemic area. *American Journal of Tropical Medicine and Hygiene* **88**, 433–440.

Bustinduy, A. L., Sousa-Figueiredo, J. C., Adriko, M., Betson, M., Fenwick, A., Kabatereine, N. and Stothard, J. R. (2013b). Fecal occult blood and fecal calprotectin as point-of-care markers of intestinal morbidity in Ugandan children with *Schistosoma mansoni* infection. *PLoS Neglected Tropical Diseases* **7**, e2542.

Carod Artal, F. J. (2012). Cerebral and spinal schistosomiasis. *Current Neurology Neuroscience Reports* **12**, 666–674.

Cavalcanti, M. G., Silva, L. F., Peralta, R. H. S., Barreto, M. G. M. and Peralta, J. M. (2013). Schistosomiasis in areas of low endemicity: a new era in diagnosis. *Trends in Parasitology* **29**, 75–82.

Colley, D. G., Binder, S., Campbell, C., King, C. H., Tchuente, L.-A. T., N'Goran, E. K., Erko, B., Karanja, D. M. S., Kabatereine, N. B., van Lieshout, L. and Rathbun, S. (2013). A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* **88**, 426–432.

Colley, D. G., Bustinduy, A. L., Secor, W. E. and King, C. H. (2014). Human schistosomiasis. *Lancet* **383**, 2253–2264.

Coulibaly, J. T., N'Goran, E. K., Utzinger, J., Doenhoff, M. J. and Dawson, E. M. (2013). A new rapid diagnostic test for detection of anti-*Schistosoma mansoni* and anti-*Schistosoma haematobium* antibodies. *Parasites and Vectors* **6**, 29.

Cringoli, G., Rinaldi, L., Albonico, M., Bergquist, R. and Utzinger, J. (2013). Geospatial (s)tools: integration of advanced epidemiological sampling and novel diagnostics. *Geospatial Health* **7**, 399–404.

Dawson, E. M., Sousa-Figueiredo, J. C., Kabatereine, N. B., Doenhoff, M. J. and Stothard, J. R. (2013). Intestinal schistosomiasis in pre school-aged children of Lake Albert, Uganda: diagnostic accuracy of a rapid test for detection of anti-schistosome antibodies. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **107**, 639–647.

Drain, P. K., Hyle, E. P., Noubary, F., Freedberg, K. A., Wilson, D., Bishai, W. R., Rodriguez, W. and Bassett, I. V. (2014). Diagnostic point-of-care tests in resource-limited settings. *Lancet Infectious Diseases* **14**, 239–249.

Farley, J. (1991). *Bilharzia: A History of Imperial Tropical Medicine.* Cambridge University Press, Cambridge, MA.

Fenwick, A., Webster, J. P., Bosque-Oliva, E., Blair, L., Fleming, F. M., Zhang, Y., Garba, A., Stothard, J. R., Gabrielli, A. F., Clements, A. C. A., Kabatereine, N. B., Toure, S., Dembele, R., Nyandindi, U., Mwansa, J. and Koukounari, A. (2009). The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. *Parasitology* **136**, 1719–1730.

French, M. D., Rollinson, D., Basanez, M. G., Mgeni, A. F., Khamis, I. S. and Stothard, J. R. (2007). School-based control of urinary schistosomiasis on Zanzibar, Tanzania: monitoring micro-haematuria with reagent strips as a rapid urological assessment. *Journal of Pediatric Urology* **3**, 364–368.

Friedman, J. F., Kanzaria, H. K. and McGarvey, S. T. (2005). Human schistosomiasis and anemia: the relationship and potential mechanisms. *Trends in Parasitology* **21**, 386–392.

Garba, A., Lamine, M. S., Djibo, A., Tahirou, A., Aouami, M. A., Alfari, A., Phillips, A. E., Fenwick, A. and Utzinger, J. (2013). Safety and efficacy of praziquantel syrup (Epiquantel (R)) against *Schistosoma haematobium* and *Schistosoma mansoni* in preschool-aged children in Niger. *Acta Tropica* **128**, 318–325.

Green, H. K., Sousa-Figueiredo, J. C., Basanez, M.-G., Betson, M., Kabatereine, N. B., Fenwick, A. and Stothard, J. R. (2011). Anaemia in Ugandan preschool-aged children: the relative contribution of intestinal parasites and malaria. *Parasitology* **138**, 1534–1545.

Gulliver, N., Agarwal, N. and Vimplis, S. (2013). Schistosomiasis, a neglected disease and 'flukey' finding at laparoscopy. *Journal of Obstetrics and Gynaecology* **33**, 423–424.

Gurarie, D., Wang, X., Bustinduy, A. L. and King, C. H. (2011). Modeling the effect of chronic schistosomiasis on childhood development and the potential for catch-up growth with different drug treatment strategies promoted for control of endemic schistosomiasis. *American Journal of Tropical Medicine and Hygiene* **84**, 773–781.

Hamburger, J., Weil, M., Turetzky, T., Ouma, J. H., Koech, D. K., Klumpp, R., Siongok, T. K. A. and Sturrock, R. F. (1989). Identification of snails infected with schistosomes by ELISA employing monoclonal-antibodies-*Schistosoma mansoni* in laboratory snails (*Biomphalaria glabrata*) and in field snails (*Biomphalaria pfeifferi*) from Kenya. *American Journal of Tropical Medicine and Hygiene* **40**, 613–619.

Hamburger, J., Hoffman, O., Kariuki, H. C., Muchiri, E. M., Ouma, J. H., Koech, D. K., Sturrock, R. F. and King, C. H. (2004). Large-scale, polymerase chain reaction-based surveillance of *Schistosoma haematobium* DNA in snails from transmission sites in coastal Kenya: a new

tool for studying the dynamics of snail infection. *American Journal of Tropical Medicine and Hygiene* **71**, 765–773.

Hamburger, J., Abbasi, I., Kariuki, C., Wanjala, A., Mzungu, E., Mungai, P., Muchiri, E. and King, C. H. (2013). Evaluation of loop-mediated isothermal amplification suitable for molecular monitoring of schistosome-infected snails in field laboratories. *American Journal of Tropical Medicine and Hygiene* **88**, 344–351.

Hotez, P. J., Savioli, L. and Fenwick, A. (2012). Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. *PLoS Neglected Tropical Diseases* **6**, e1475.

Jaber, O. I. and Kirby, P. A. (2013). Spinal cord schistosomiasis: unexpected postmortem finding. *American Journal of Clinical Pathology* **140**, 33–36.

Jordan, P. (2000). From Katayama to the Dakhla Oasis: the beginning of epidemiology and control of bilharzia. *Acta Tropica* **77**, 9–40.

Kane, R. A., Stothard, J. R., Rollinson, D., Leclipteux, T., Evraerts, J., Standley, C. J., Allan, F., Betson, M., Kaba, R., Mertens, P. and Laurent, T. (2013). Detection and quantification of schistosome DNA in freshwater snails using either fluorescent probes in real-time PCR or oligochromatographic dipstick assays targeting the ribosomal intergenic spacer. *Acta Tropica* **128**, 241–249.

Kato-Hayashi, N., Yasuda, M., Yuasa, J., Isaka, S., Haruki, K., Ohmae, H., Osada, Y., Kanazawa, T. and Chigusa, Y. (2013). Use of cell-free circulating schistosome DNA in serum, urine, semen, and saliva to monitor a case of refractory imported schistosomiasis hematobia. *Journal of Clinical Microbiology* **51**, 3435–3438.

King, C. H. and Bertsch, D. (2013). Meta-analysis of urine heme dipstick diagnosis of *Schistosoma haematobium* infection, including low-prevalence and previously-treated populations. *PLoS Neglected Tropical Diseases* **7**, e2431.

Kjetland, E. F., Leutscher, P. D. and Ndhlovu, P. D. (2012). A review of female genital schistosomiasis. *Trends in Parasitology* **28**, 58–65.

Kjetland, E. F., Hegertun, I. E., Baay, M. F., Onsrud, M., Ndhlovu, P. D. and Taylor, M. (2014). Genital schistosomiasis and its unacknowledged role on HIV transmission in the STD intervention studies. *International Journal of STD and AIDS*. doi: 10.1177/0956462414523743.

Knopp, S., Becker, S. L., Ingram, K. J., Keiser, J. and Utzinger, J. (2013*a*). Diagnosis and treatment of schistosomiasis in children in the era of intensified control. *Expert Review of Anti-Infective Therapy* **11**, 1237–1258.

Knopp, S., Person, B., Ame, S. M., Mohammed, K. A., Ali, S. M., Khamis, I. S., Rabone, M., Allan, F., Gouvras, A., Blair, L., Fenwick, A., Utzinger, J. and Rollinson, D. (2013*b*). Elimination of schistosomiasis transmission in Zanzibar: baseline findings before the onset of a randomized intervention trial. *PLoS Neglected Tropical Diseases* **7**, e2474.

Knopp, S., Stothard, J. R., Rollinson, D., Mohammed, K. A., Khamis, I. S., Marti, H. and Utzinger, J. (2013*c*). From morbidity control to transmission control: time to change tactics against helminths on Unguja Island, Zanzibar. *Acta Tropica* **128**, 412–422.

Koukounari, A., Fenwick, A., Whawell, S., Kabatereine, N. B., Kazibwe, F., Tukahebwa, E. M., Stothard, J. R., Donnelly, C. A. and Webster, J. P. (2006). Morbidity indicators of *Schistosoma mansoni*: relationship between infection and anemia in Ugandan schoolchildren before and after praziquantel and albendazole chemotherapy. *American Journal of Tropical Medicine and Hygiene* **75**, 278–286.

Lammie, P. J., Moss, D. M., Goodhew, E. B., Hamlin, K., Krolewiecki, A., West, S. K. and Priest, J. W. (2012). Development of a new platform for neglected tropical disease surveillance. *International Journal for Parasitology* **42**, 797–800.

Leiper, R. (1915). Report on the results of the bilharzia mission in Egypt, 1915, Part I. Transmission. *Journal of the Royal Army Medical Corps* **25**, 1–55.

Levecke, B., Brooker, S. J., Knopp, S., Steinmann, P., Sousa-Figueiredo, J. C., Stothard, J. R., Utzinger, J. and Vercruysse, J. (2014). Effect of sampling and diagnostic effort on the assessment of schistosomiasis and soil-transmitted helminthiasis and drug efficacy: a meta-analysis of six drug efficacy trials and one epidemiological survey. *Parasitology* **141**, 1826–1840.

Lodh, N., Mwansa, J. C. L., Mutengo, M. M. and Shiff, C. J. (2013). Diagnosis of *Schistosoma mansoni* without the stool: comparison of three diagnostic tests to detect *Schistosoma mansoni* infection from filtered urine in Zambia. *American Journal of Tropical Medicine and Hygiene* **89**, 46–50.

Lodh, N., Naples, J. M., Bosompem, K. M., Quartey, J. and Shiff, C. J. (2014). Detection of parasite-specific DNA in urine sediment obtained by filtration differentiates between single and mixed infections of *Schistosoma mansoni* and *S. haematobium* from endemic areas in Ghana. *PLoS ONE* **9**, e91144.

Logan, S., Armstrong, M., Moore, E., Nebbia, G., Jarvis, J., Suvari, M., Bligh, J., Chiodini, P. L., Brown, M. and Doherty, T. (2013). Short report: acute schistosomiasis in travelers: 14 years' experience at the Hospital for Tropical Diseases, London. *American Journal of Tropical Medicine and Hygiene* **88**, 1032–1034.

Meltzer, E. and Schwartz, E. (2013). Schistosomiasis: current epidemiology and management in travelers. *Current infectious disease reports* **15**, 211–215.

Mitchell, S. and Pagano, M. (2012). Pooled testing for effective estimation of the prevalence of *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* **87**, 850–861.

Montresor, A. (2011). Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **105**, 361–363.

Morad, N. A. and Khan, A. R. (2001). Clinicopathological patterns and distribution of schistosomiasis in Asir Region. *Saudi Medical Journal* **22**, 520–522.

Mull, B., Secor, E., Foo, K. and Hill, V. (2010). *Schistosoma mansoni* cercariae detection in water samples using dead-end ultrafiltration and PCR. *American Journal of Tropical Medicine and Hygiene* **83**, 108.

Mutapi, F. (2011). Improving diagnosis of urogenital schistosome infection. *Expert Review of Anti-Infective Therapy* **9**, 863–865.

Olives, C., Valadez, J. J., Brooker, S. J. and Pagano, M. (2012). Multiple category-lot quality assurance sampling: a new classification system with application to schistosomiasis control. *PLoS Neglected Tropical Diseases* **6**, e1806.

Olliaro, P., Delgado-Romero, P. and Keiser, J. (2014). The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). *Journal of Antimicrobial Chemotherapy* **69**, 863–870.

Oshish, A., AlKohlani, A., Hamed, A., Kamel, N., AlSoofi, A., Farouk, H., Ben-Ismail, R., Gabrielle, A. F., Fenwick, A. and French, M. D. (2011). Towards nationwide control of schistosomiasis in Yemen: a pilot project to expand treatment to the whole community. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **105**, 617–627.

Paugam, A., Rabetokotany, F. R., Lesle, F., Challier, S., Dahane, N. and Yera, H. (2013). Parasitic hypereosinophilia. Practical use of diagnostic tests. *Immuno-Analyse and Biologie Specialisee* **28**, 245–250.

Poole, H., Terlouw, D. J., Naunje, A., Mzembe, K., Stanton, M., Betson, M., Lalloo, D. G. and Stothard, J. R. (2014). Schistosomiasis in pre-school-age children and their mothers in Chikhwawa district, Malawi with notes on characterization of schistosomes and snails. *Parasites and Vectors* **7**, 153.

Prichard, R. K., Basanez, M. G., Boatin, B. A., McCarthy, J. S., Garcia, H. H., Yang, G. J., Sripa, B. and Lustigman, S. (2012). A research agenda for helminth diseases of humans: intervention for control and elimination. *PLoS Neglected Tropical Diseases* **6**, e1549.

Pullan, R. L., Freeman, M. C., Gething, P. W. and Brooker, S. J. (2014). Geographical inequalities in use of improved drinking water supply and sanitation across sub-Saharan Africa: mapping and spatial analysis of cross-sectional survey data. *PLoS Medicine* **11**, e1001626.

Robinson, E., Picon, D., Sturrock, H. J., Sabasio, A., Lado, M., Kolaczinski, J. and Brooker, S. (2009). The performance of haematuria reagent strips for the rapid mapping of urinary schistosomiasis: field experience from Southern Sudan. *Tropical Medicine and International Health* **14**, 1484–1487.

Rollinson, D., Stothard, J. R. and Southgate, V. R. (2001). Interactions between intermediate snail hosts of the genus *Bulinus* and schistosomes of the *Schistosoma haematobium* group. *Parasitology* **123**, S245–S260.

Rollinson, D., Klinger, E. V., Mgeni, A. E., Khamis, I. S. and Stothard, J. R. (2005). Urinary schistosomiasis on Zanzibar: application of two novel assays for the detection of excreted albumin and haemoglobin in urine. *Journal of Helminthology* **79**, 199–206.

Rollinson, D., Webster, J. P., Webster, B., Nyakaana, S., Jorgensen, A. and Stothard, J. R. (2009). Genetic diversity of schistosomes and snails: implications for control. *Parasitology* **136**, 1801–1811.

Rollinson, D., Knopp, S., Levitz, S., Stothard, J. R., Tchuente, L.-A. T., Garba, A., Mohammed, K. A., Schur, N., Person, B., Colley, D. G. and Utzinger, J. (2013). Time to set the agenda for schistosomiasis elimination. *Acta Tropica* **128**, 423–440.

Sady, H., Al-Mekhlafi, H. M., Mahdy, M. A. K., Lim, Y. A. L., Mahmud, R. and Surin, J. (2013). Prevalence and associated factors of schistosomiasis among children in Yemen: implications for an effective control programme. *PLoS Neglected Tropical Diseases* **7**, e2377.

Scherrer, A. U., Sjoeberg, M. K., Allangba, A., Traore, M., Lohourignon, L. K., Tschannen, A. B., N'Goran, E. K. and

Utzinger, J. (2009). Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration. *Acta Tropica* **109**, 226–231.

Silva-Moraes, V., Ferreira, J. M. S., Coelho, P. M. Z. and Grenfell, R. F. Q. (2014). Biomarkers for schistosomiasis: towards an integrative view of the search for an effective diagnosis. *Acta Tropica* **132**, 75–79.

Solomon, A. W., Engels, D., Bailey, R. L., Blake, I. M., Brooker, S., Chen, J.-X., Chen, J.-H., Churcher, T. S., Drakeley, C. J., Edwards, T., Fenwick, A., French, M., Gabrielli, A. F., Grassly, N. C., Harding-Esch, E. M., Holland, M. J., Koukounari, A., Lammie, P. J., Leslie, J., Mabey, D. C., Rhajaoui, M., Secor, W. E., Stothard, J. R., Wei, H., Willingham, A. L., Zhou, X.-N. and Peeling, R. W. (2012). A diagnostics platform for the integrated mapping, monitoring, and surveillance of neglected tropical diseases: rationale and target product profiles. *PLoS Neglected Tropical Diseases* **6**, e1746.

Sousa-Figueiredo, J. C., Basanez, M.-G., Khamis, I. S., Garba, A., Rollinson, D. and Stothard, J. R. (2009). Measuring morbidity associated with urinary schistosomiasis: assessing levels of excreted urine albumin and urinary tract pathologies. *PLoS Neglected Tropical Diseases* **3**, e526.

Sousa-Figueiredo, J. C., Betson, M., Atuhaire, A., Arinaitwe, M., Navaratnam, A. M. D., Kabatereine, N. B., Bickle, Q. and Stothard, J. R. (2012). Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. *PLoS Neglected Tropical Diseases* **6**, e1864.

Standley, C. J. and Stothard, J. R. (2010). Towards defining appropriate strategies for targeted NTD control. *Tropical Medicine and International Health* **15**, 772–773.

Standley, C. J., Adriko, M., Alinaitwe, M., Kazibwe, F., Kabatereine, N. B. and Stothard, J. R. (2009). Intestinal schistosomiasis and soil-transmitted helminthiasis in Ugandan schoolchildren: a rapid mapping assessment. *Geospatial Health* **4**, 39–53.

Standley, C. J., Vounatsou, P., Gosoniu, L., McKeon, C., Adriko, M., Kabatereine, N. B. and Stothard, J. R. (2013). Micro-scale investigation of intestinal schistosomiasis transmission on Ngamba and Kimi islands, Lake Victoria, Uganda. *Acta Tropica* **128**, 353–364.

Stete, K., Krauth, S. J., Coulibaly, J. T., Knopp, S., Hattendorf, J., Mueller, I., Lohourignon, L. K., Kern, W. V., N'Goran, E. K. and Utzinger, J. (2012). Dynamics of *Schistosoma haematobium* egg output and associated infection parameters following treatment with praziquantel in school-aged children. *Parasites and Vectors* **5**, 298.

Stothard, J. R. (2009). Improving control of African schistosomiasis: towards effective use of rapid diagnostic tests within an appropriate disease surveillance model. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **103**, 325–332.

Stothard, J. R., Mgeni, A. F., Khamis, S., Seto, E., Ramsan, M., Hubbard, S. J. and Kristensen, T. K. (2002*a*). Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 21 February 2002 – fresh from the field – new insights into the transmission biology of urinary schistosomiasis in Zanzibar. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **96**, 470–475.

Stothard, J. R., Mgeni, A. F., Khamis, S., Seto, E., Ramsan, M. and Rollinson, D. (2002*b*). Urinary schistosomiasis in schoolchildren on Zanzibar Island (Unguja), Tanzania: a parasitological survey supplemented with questionnaires. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **96**, 507–514.

Stothard, J. R., Kabatereine, N. B., Tukahebwa, E. M., Kazibwe, F., Rollinson, D., Mathieson, W., Webster, J. P. and Fenwick, A. (2006). Use of circulating cathodic antigen (CCA) dipsticks for detection of intestinal and urinary schistosomiasis. *Acta Tropica* **97**, 219–228.

Stothard, J. R., French, M. D., Khamis, I. S., Basanez, M. G. and Rollinson, D. (2009*a*). The epidemiology and control of urinary schistosomiasis and soil-transmitted helminthiasis in school children on Unguja Island, Zanzibar. *Transactions of the Royal Society for Tropical Medicine and Hygiene* **103**, 1031–1044.

Stothard, J. R., Sousa-Figueiredo, J. C., Khamis, I. S., Garba, A. and Rollinson, D. (2009*b*). Urinary schistosomiasis-associated morbidity in schoolchildren detected with urine albumin-to-creatinine ratio (UACR) reagent strips. *Journal of Pediatric Urology* **5**, 287–291.

Stothard, J. R., Sousa-Figueiredo, J. C., Standley, C., Van Dam, G. J., Knopp, S., Utzinger, J., Ameri, H., Khamis, A. N., Khamis, I. S., Deelder, A. M., Mohammed, K. A. and Rollinson, D. (2009*c*). An evaluation of urine-CCA strip test and fingerprick blood SEA-ELISA for detection of urinary schistosomiasis in schoolchildren in Zanzibar. *Acta Tropica* **111**, 64–70.

Stothard, J. R., Sousa-Figueiredo, J. C., Betson, M., Adriko, M., Arinaitwe, M., Rowell, C., Besiyge, F. and Kabatereine, N. B. (2011). *Schistosoma mansoni* infections in young children: when are schistosome antigens in urine, eggs in stool and antibodies to eggs first detectable? *PLoS Neglected Tropical Diseases* **5**, e938.

Stothard, J. R., Sousa-Figueiredo, J. C., Betson, M., Bustinduy, A. and Reinhard-Rupp, J. (2013*a*). Schistosomiasis in African infants and preschool children: let them now be treated! *Trends in Parasitology* **29**, 197–205.

Stothard, J. R., Sousa-Figueiredo, J. C. and Navaratnam, A. M. D. (2013*b*). Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. *Expert Review of Anti-Infective Therapy* **11**, 733–752.

Stothard, J. R., Bustinduy, A. and Montresor, A. (2014). Preventive chemotherapy for schistosomiasis and soil-transmitted helminthiasis by cotreatment with praziquantel and albendazole. *Clinical Investigation* **4**, 163–176.

Strahan, R., McAdam, D. and Schneider, M. E. (2013). Sonographic response in the liver and urinary bladder of children 14 months after treatment for schistosomiasis. *Tropical Doctor* **43**, 71–74.

Tchueme-Tchuente, L.-A., Momo, S. C., Stothard, J. R. and Rollinson, D. (2013). Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon. *Acta Tropica* **128**, 275–283.

Terer, C. C., Bustinduy, A. L., Magtanong, R. V., Muhoho, N., Mungai, P. L., Muchiri, E. M., Kitron, U., King, C. H. and Mutuku, F. M. (2013). Evaluation of the health-related quality of life of children in *Schistosoma haematobium* – endemic communities in Kenya: a cross-sectional study. *PLoS Neglected Tropical Diseases* **7**, e2106.

Utzinger, J., Raso, G., Brooker, S., de Savigny, D., Tanner, M., Ornbjerg, N., Singer, B. H. and N'Goran, E. K. (2009). Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. *Parasitology* **136**, 1859–1874.

Utzinger, J., N'Goran, E. K., Caffrey, C. R. and Keiser, J. (2011). From innovation to application: social–ecological context, diagnostics, drugs and integrated control of schistosomiasis. *Acta Tropica* **120**, S121–S137.

van Dam, G. J., de Dood, C. J., Lewis, M., Deelder, A. M., van Lieshout, L., Tanke, H. J., van Rooyen, L. H. and Corstjens, P. L. A. M. (2013). A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of *Schistosoma* circulating anodic antigen. *Experimental Parasitology* **135**, 274–282.

Vinkeles-Melchers, N. V. S., van Dam, G. J., Shaproski, D., Kahama, A. I., Brienen, E. A. T., Vennervald, B. J. and van Lieshout, L. (2014). Diagnostic performance of *Schistosoma* real-time PCR in urine samples from Kenyan children infected with *Schistosoma haematobium*: day-to-day variation and follow-up after praziquantel treatment. *PLoS Neglected Tropical Diseases* **8**. doi: 10.1371/journal.pntd.0002807.

Warrell, D. A. (1993). Leishmaniasis, malaria and schistosomiasis in Saudi Arabia. *Saudi Medical Journal* **14**, 203–208.

Webster, B. L., Diaw, O. T., Seye, M. M., Faye, D. S., Stothard, J. R., Sousa-Figueiredo, J. C. and Rollinson, D. (2013). Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. *Acta Tropica* **128**, 292–302.

Webster, J. P., Koukounari, A., Lamberton, P. H. L., Stothard, J. R. and Fenwick, A. (2009). Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. *Parasitology* **136**, 1789–1799.

WHO (2006). *Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers*. World Health Organization, Geneva.

WHO (2013). *Schistosomiasis: Progress Report 2001–2011 and Strategic Plan 2012–2020*. World Health Organization, Geneva.

Won, K. Y., Abudho, B., Blackstock, A. J., Montgomery, S. P., Kennedy, E. D., Person, B., Mwinzi, P. N. M., Ochola, E. A., Foo, K. T., Hightower, A. W., Karanja, D. M. S. and Secor, W. E. (2014). Assessment of quality of life as a tool for measuring morbidity due to *Schistosoma mansoni* infection and the impact of treatment. *American Journal of Tropical Medicine and Hygiene* **90**, 322–328.